A new observational study of more than 8,000 prostate tumors shows that B7‑H3 (CD276) expression helps shape prognosis and could open new paths for targeted therapies. Researchers analyzed 8,157 prostate cancer samples with matched DNA and RNA data, stratifying them by tissue site, hormone‑sensitivity status, and self‑reported race, then examined how B7‑H3 levels related to […]
A new study in Nature Biotechnology describes a DNA-based drug system that can turn on only when it finds the right combination of markers on a cancer cell. This matters because many cancer drugs are powerful but also damage healthy tissue, so the main challenge is not only killing the tumor, but doing it with […]
A novel double-masked T-cell engager targeting prostate-specific membrane antigen (PSMA), called JANX014, has entered phase 1 testing in patients with metastatic castration-resistant prostate cancer (mCRPC). The first-in-human, open-label, multicenter trial, which dosed its initial participant in mid-April 2026, evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity through ascending intravenous doses administered as monotherapy to […]
PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]
Adoptive transfer of chimeric antigen receptor (CAR) T cells has worked well in some blood cancers, but it has been much less effective in solid tumors like prostate cancer. One reason is the strong cytokine release and strong immune suppression in the tumor area. A new study has designed a PSMA‑targeted CAR that uses CD16A, […]
For prostate cancer patients with low expression of PSMA or with neuroendocrine prostate cancer or NEPC (a population growing in size precisely because better treatments are forcing tumors to adapt), a new preclinical study offers a credible precision-targeted strategy: a radiotheranostic pair built on the CEACAM5 surface antigen that produced complete tumor responses in every […]
Bispecific T cell engagers, while conceptually powerful, have carried a toxicity profile that constrains their clinical utility. AZD8359, a novel trispecific T cell engager now entering its first-in-human clinical trial, represents a thoughtful attempt to resolve that toxicity problem at the molecular engineering level, and its preclinical data are among the most compelling seen in this […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! The annual AACR 2026 meeting has just started and we already have some very interesting clinical and preclinical studies for you. Stay strong and fight on! Picture: Borghetto sul Mincio (near my place), I cross the bridge quite often, […]
HSK46575, a novel CYP11A1 inhibitor designed to suppress the entire steroidogenesis pathway, continues to generate interest in advanced prostate cancer, with new early-phase clinical data providing a clearer picture of its activity and tolerability in patients. At the latest data cut-off, 27 patients with advanced prostate cancer had been treated across dose-escalation cohorts ranging from […]
A new experimental compound, ITRI-148, may represent a meaningful shift in how advanced prostate cancer is treated, particularly in patients who develop resistance to current androgen receptor (AR)-targeted therapies. Resistance to drugs like enzalutamide is frequently driven by AR splice variants such as AR-V7, which lack the ligand-binding domain (LBD) targeted by existing therapies, allowing […]